Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 201–300 of 1,000
Zhang, T., Zhang, C., Zhang, Y., Tang, F., Li, H., Zhang, Q., Lin, H., Wu, S., Liu, Y., & Xue, F. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.049 · Cited by 73
Cheah, I. K., Tang, R., Ye, P., Yew, T. S. Z., Lim, K. H. C., & Halliwell, B. (2016) · Free Radical Research · doi:10.3109/10715762.2015.1099642 · Cited by 70
“most common causes of chronic liver disease [7].”
BackgroundReddy, D. S., Bharath, R., & Rajalakshmi, P. (2018) · IEEE International Conference on e-Health Networking, Applications and Services (Healthcom) · doi:10.1109/healthcom.2018.8531118 · Cited by 81
“that addressing the challenges in accurate identification of fatty liver is the need of the hour [2].”
BackgroundEfficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis
Wang, H., Wang, L., Cheng, Y., Xia, Z., Liao, Y., & Cao, J. (2018) · Biomedical Reports · doi:10.3892/br.2018.1100 · Cited by 70
“Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic fat accumulation in patients with little to no history of alcohol consumption (1).”
Abo-Amer, Y. E.-E., Sabal, A. A., Ahmed, R. F., Hasan, N. F. E., Refaie, R., Mostafa, S. M., Mohamed, A. A., Khalil, M., Elagawy, W., & Abd-Elsalam, S. M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s237866 · Cited by 70
Shi, L., Liu, Z. W., Li, Y., Gong, C., Zhang, H., Li, S., Huang, C. Y., & Li, M. (2012) · PubMed · doi:10.3967/0895-3988.2012.04.002 · Cited by 55
“Many epidemiological studies have been conducted worldwide and have indicated that NAFLD affects 20% to 30% of the general population in Western countries([3]) and 12% to 24% in Asian countries([4]).”
BackgroundPrevalence and associated metabolic factors of fatty liver disease in the elderly
Wang, Z., Xu, M., Peng, J., Jiang, L., Hu, Z., Wang, H., Zhou, S., Zhou, R., Hultström, M., & Lai, E. Y. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.05.059 · Cited by 76
Alempijevic, T. M., Lalošević, M. S., Dumic, I., Jocic, N., Marković, A. P., Dragašević, S., Jovicic, I., Lukić, S., Popović, D., & Milosavljević, T. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/6070135 · Cited by 71
Paik, J., Golabi, P., Younoszai, Z., Mishra, A., Trimble, G., & Younossi, Z. M. (2019) · Liver International · doi:10.1111/liv.13992 · Cited by 68
Cho, H. C. (2016) · Gut and Liver · doi:10.5009/gnl14444 · Cited by 68
“It has a wide histological spectrum that ranges from simple hepatic steatosis to steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma.(3,6) A high prevalence of NAFLD, which ranges from 18% to 45%, has been reported among various ethnic groups, and it is associated with the growing obesity epidemic.”
BackgroundGao, M., Zhao, W., Li, C., Xie, X., Li, M., Bi, Y., Fang, F., Du, Y., & Liu, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.078 · Cited by 67
Sex-based differences in hepatic and skeletal muscle triglyceride storage and metabolism
Beaudry, K. M., & Devries, M. C. (2019) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0635 · Cited by 65
“The prevalence of NAFLD is 20-30% in the general population; however, this increases to 80-90% in obese individuals (Bellentani et al. 2010).”
BackgroundBathish, B., Robertson, H., Dillon, J. F., Dinkova‐Kostova, A. T., & Hayes, J. D. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.06.226 · Cited by 76
The potential of silymarin for the treatment of hepatic disorders
Hellerbrand, C., Schattenberg, J. M., Peterburs, P., Lechner, A., & Brignoli, R. (2016) · Clinical Phytoscience · doi:10.1186/s40816-016-0019-2 · Cited by 70
Pakravan, H., Ahmadian, M., Fani, A., Aghaee, D., Brumanad, S., & Pakzad, B. (2017) · Advanced Biomedical Research · doi:10.4103/2277-9175.204593 · Cited by 67
“reported that the prevalence of NAFLD in the general population is approximately 20–30%.[9,10]”
BackgroundA “systems medicine” approach to the study of non-alcoholic fatty liver disease
Petta, S., Valenti, L. V. C., Bugianesi, E., Targher, G., Bellentani, S., Bonino, F., Ferrannini, E., Loguercio, C., Lonardo, A., Marra, F., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.10.027 · Cited by 70
“The clinico-epidemiological features of high-risk groups play a ajor role in guiding the physician to suspect NAFLD and NASH in he single patient (age, sex, ethnicity, body weight and metabolic tatus) [1–6], whereas serum transaminases do not qualify as markrs of NAFLD or NASH [29].”
BackgroundSelf-citationWang, W., Li, Q., Chai, W., Sun, C., Zhang, T., Zhao, C., Yuan, Y., Wang, X., Liu, H., & Ye, H. (2019) · Food Science & Nutrition · doi:10.1002/fsn3.1118 · Cited by 71
Guo, W., Lei, L., Shi, X., Li, R., Wang, Q., Han, J. Z., Yang, L., Chen, L., & Zhou, B. (2021) · Environmental Science & Technology · doi:10.1021/acs.est.1c01476 · Cited by 67
Pais, R., Rusu, E. E., Zilisteanu, D. S., Cîrciumaru, A., Micu, L., Voiculescu, M., Poynard, T., & Ratziu, V. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.12.001 · Cited by 66
Template to improve glycemic control without reducing adiposity or dietary fat
Krishnapuram, R., Dhurandhar, E. J., Dubuisson, O. S., Kirk-Ballard, H., Bajpeyi, S., Butte, N. F., SOTHERN, M. S., Larsen-Meyer, E., Chalew, S. A., Bennett, B., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00703.2010 · Cited by 68
“The prevalence of NAFLD is about 70–80% in adults with type 2 diabetes or obesity (5, 42, 56), 3–10%, in all children, and up to 40–70% in obese children (5).”
BackgroundZhang, D., Zhang, J., Wu, X., Liu, Y., Gu, S., Zhu, G., Wang, Y.-Z., Gao-lin, L., & Li, X. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00238 · Cited by 66
Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease
Oliveira, C. P., de Lima Sanches, P., de Abreu-Silva, E. O., & Marcadenti, A. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4597246 · Cited by 59
“It is estimated that onequarter of theAmerican population is overweight, and 80%of these have NAFLD [4].”
BackgroundGao, X., Albert Hofman, D., Hu, Y., Lin, H., Zhu, C., Jeekel, J. J., Jin, X., Wang, J., Gao, J., Yin, Y., et al. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9525-6 · Cited by 64
An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Marin, V., Rosso, N., Ben, M. D., Raseni, A., Boschelle, M., Degrassi, C., Němečková, I., Nachtigal, P., Avellini, C., Tiribelli, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158817 · Cited by 67
“Indeed, is expected that in the next 20 years the most frequent indication for liver transplantation will be associated to metabolic disorders rather than the current viral-related damages [2,3].”
BackgroundDistinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity
Subudhi, S., Drescher, H. K., Dichtel, L. E., Bartsch, L. M., Chung, R. T., Hutter, M. M., Gee, D. W., Meireles, O. R., Witkowski, E. R., Gelrud, L. G., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1789 · Cited by 66
Lytle, K. A., Wong, C. P., & Jump, D. Β. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173376 · Cited by 68
Zhu, L., Jiang, J., Zhai, X., Baecker, A. S., Peng, X., Qian, J., Zhou, M., Song, C., Zhou, Y., Xu, J., et al. (2018) · Liver International · doi:10.1111/liv.13933 · Cited by 68
Ferreira, D. M. S., Simão, A. L., Rodrigues, C. M. P., & Castro, R. E. (2014) · FEBS Journal · doi:10.1111/febs.12806 · Cited by 82
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
Panera, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15079 · Cited by 60
Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease
Nobili, V., Siotto, M., Bedogni, G., Ravà, L., Pietrobattista, A., Panera, N., Alisi, A., & Squitti, R. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31827aced4 · Cited by 61
Self-citationHu, J., Xu, Y., He, Z., Zhang, H., Lian, X., Zhu, T., Liang, C., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22755 · Cited by 61
“In recent years, NAFLD has already become a familiar clinical diagnosis and its prevalence and incidence increase dramatically and consistently in the general population [6].”
BackgroundBarata, L., Feitosa, M. F., Bielak, L. F., Halligan, B., Baldridge, A. S., Guo, X., Yerges‐Armstrong, L. M., Smith, A. V., Yao, J., Palmer, N. D., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1353 · Cited by 59
“(2,3,16) Approximately 80%90% of adults with obesity (BMI ≥ 30 kg/m2) have hepatic steatosis,(17) while 20%-80% of individuals with hepatic steatosis also have higher levels of triglyceride (TG) and low-density lipoprotein (LDL) cholesterol but lower levels of high- density lipoprotein (HDL) cholesterol.”
BackgroundOtgonsuren, M., Stepanova, M., Gerber, L. H., & Younossi, Z. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2446-3 · Cited by 64
“Although these associations are consistent with that previously reported [16–19], our study is the first to use a large general population-based cohort of individuals with radiologically proven NAFLD for whom in-depth clinical and laboratory data are available.”
ResultBlack, L. J., Jacoby, P., Ping‐Delfos, W. C. S., Mori, T. A., Beilin, L. J., Olynyk, J. K., Ayonrinde, O. T., Huang, R. C., Holt, P. G., Hart, P. H., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12541 · Cited by 60
Thyroid hormone action and liver disease, a complex interplay
Marino, L., Kim, A., Ni, B., & Celi, F. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000551 · Cited by 63
“[112] NAFLD is initiated by lipid accumulation in hepatocytes, [113,114] which leads to a spectrum of liver dysfunction ranging from excess lipid storage (hepato-steatosis) to progressive NASH, that in turn increases the risk for cirrhosis and HCC. [ 115 ] NAFLD is considered the hepatic phenotype…”
Wang, X., Lu, Y., Wang, E., Zhang, Z., Xiong, X., Zhang, H., Lu, J., Zheng, S., Yang, J., Xia, X., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.029 · Cited by 60
“the prevalence of NAFLD is higher in men than in women [2].”
BackgroundPatel, T. P., Rawal, K., Soni, S., & Gupta, S. S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.07.028 · Cited by 60
Astaxanthin as a Potential Protector of Liver Function: A Review
Jt, C., & Kotani, K. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2672w · Cited by 60
“, hepatitis viruses) [10-12].”
Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes
Krogstad, V., Peric, A., Robertsen, I., Kringen, M. K., Vistnes, M., Hjelmesaeth, J. S., Sandbu, R., Johnson, L. K., Angeles, P. C., Jansson‐Löfmark, R., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.027 · Cited by 59
Steatosis does not impair liver regeneration after partial hepatectomy
Sydor, S., Gu, Y., Schlattjan, M., Bechmann, L. P., Rauen, U., Best, J., Paul, A., Baba, H. A., Sowa, J., Gerken, G., et al. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.142 · Cited by 63
Liao, Y., Yang, K., Lee, M.-J., Huang, K., Chen, J.-D., & Yeh, C. (2016) · Scientific Reports · doi:10.1038/srep35083 · Cited by 58
“= + + E f i f i ( ) log( ( )), (5) i N”
MethodMansour‐Ghanaei, R., Mansour‐Ghanaei, F., Naghipour, M., & Joukar, F. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_243_18 · Cited by 58
“[3] Prevalence of NAFLD in the world is about 25%,[4] in non‐obese Asian‐Pacific individuals, it is 15–21%,[5] in American adults, it is 30%, and in Italy, it has been reported to be 25%.[6] In the Iranian general population,”
BackgroundBonfleur, M. L., Borck, P. C., Ribeiro, R. A., Caetano, L. C., Soares, G. M., Carneiro, E. M., & Balbo, S. L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.019 · Cited by 61
Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
Rosso, N., Chávez-Tapia, N. C., Tiribelli, C., & Bellentani, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9038 · Cited by 65
Self-citationGonciarz, M., Bielański, W., Partyka, R., Brzozowski, T., Konturek, P. C., Eszyk, J., Celiński, K., Reiter, R. J., & Konturek, S. J. (2013) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2012.01023.x · Cited by 56
“The reported prevalence of NAFLD and NASH in the general population of Western countries is about 30% and 2–3%, respectively [2].”
BackgroundAkie, T. E., Liu, L., Nam, M., Lei, S., & Cooper, M. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125617 · Cited by 56
“Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming one of the leading causes of liver disease in Western societies [1].”
BackgroundElevation of circulating microRNA levels in obese children compared to healthy controls
Thompson, M. D., Cismowski, M. J., Serpico, M. R., Pusateri, A. J., & Brigstock, D. R. (2017) · Clinical Obesity · doi:10.1111/cob.12192 · Cited by 56
“Current estimates indicate that between 3% and 10% of children have evidence of NAFLD, and more strikingly, 70–90% of obese children have NAFLD (7,8).”
BackgroundPatel, N. S., Peterson, M. R., Lin, G. Y., Feldstein, A., Schnabl, B., Bettencourt, R., Seki, E., Sirlin, C. B., & Loomba, R. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/498296 · Cited by 54
“In particular, diabetes and worsening of metabolic factors have been linked to the development of NASH and advanced fibrosis in patients with NAFLD [38– 40].”
BackgroundInfluentialMa, H., Xu, C., Xu, L., Yu, C., Miao, M., & Li, Y. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-3 · Cited by 61
Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease
Briskey, D. R., Heritage, M. L., Jaskowski, L., Peake, J. M., Gobe, G. C., Subramaniam, V. N., Crawford, D. H., Campbell, C. M., & Vitetta, L. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16645055 · Cited by 58
“NAFLD has been found in 14% of lean individuals, whereas it afflicts 80-90% of obese individuals [Bellentani et al. 2010; Niaz et al. 2011].”
BackgroundGinkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice
Jeong, H.-S., Kim, K., Lee, I., Park, J. Y., Kim, Y., Kim, K., & Jang, H.-J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.114 · Cited by 55
Li, J., Li, X., Li, Z., Zhang, L., Liu, Y., Ding, H., & Yin, S. (2017) · Food & Function · doi:10.1039/c7fo00290d · Cited by 57
Korovljev, D., Štajer, V., Ostojic, J. N., LeBaron, T. W., & Ostojić, S. M. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.03.008 · Cited by 55
A weighty problem: metabolic perturbations and the obesity-cancer link
O’Flanagan, C. H., Bowers, L. W., & Hursting, S. D. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0022 · Cited by 61
“NAFLD is one of the most common chronic diseases [100, 101], with the incidence in both adults and children rising rapidly [101, 102].”
Acharya, U. R., Fujita, H., Sudarshan, V. K., Mookiah, M. R. K., Koh, J. E., Tan, J. H., Hagiwara, Y., Chua, C. K., Junnarkar, S. P., Vijayananthan, A., et al. (2015) · Information Fusion · doi:10.1016/j.inffus.2015.12.007 · Cited by 56
Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
Domínguez, V. M., González-Casas, R., Jiménez-Ridruejo, J. M., García-Buey, L., & Moreno‐Otero, R. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000700006 · Cited by 79
“It is estimated that NAFLD is the first cause of chronic elevation of liver function texts in the USA and it is believed that cryptogenetic cirrhosis may be associated with it (3).”
BackgroundInfluentialBruno, S., Saibeni, S., Bagnardi, V., Vandelli, C., Luca, M. D., Felder, M., Fracanzani, A. L., Prisco, C., Vitaliani, G., Simone, L., et al. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.110 · Cited by 56
Xu, H., Hsu, Y., Chang, C., Wei, K., & Lin, C. (2015) · Hepatology International · doi:10.1007/s12072-015-9690-5 · Cited by 56
Bartolini, D., Torquato, P., Barola, C., Russo, A., Rychlicki, C., Giusepponi, D., Bellezza, G., Sidoni, A., Galarini, R., Svegliati‐Baroni, G., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.06.003 · Cited by 53
“Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition of rich and developing countries now affecting about one third of the global population [1, 2].”
BackgroundNobili, V., Alisi, A., Mosca, A., Della Corte, C., Veraldi, S., De Vito, R., De Stefanis, C., D'Oria, V., Jahnel, J., Zohrer, E., et al. (2018) · Liver International · doi:10.1111/liv.13531 · Cited by 51
“[2], the prevalence of NAFLD in obese children living in Western countries, such as Italy, is estimated to be between 40 and 70%.”
BackgroundFan, M., Choi, Y., Tang, Y., Bae, S. M., Yang, H. P., & Kim, E. (2019) · Nutrients · doi:10.3390/nu11112586 · Cited by 56
The benefits of exercise for patients with non-alcoholic fatty liver disease
Keating, S. E., George, J., & Johnson, N. A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1075392 · Cited by 53
“Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in many countries [1] and encompasses disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH).”
BackgroundRole of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 51
Doycheva, I., Patel, N., Peterson, M., & Loomba, R. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.008 · Cited by 51
Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease
Soronen, J., Yki‐Järvinen, H., Zhou, Y., Sädevirta, S., Sarin, A., Leivonen, M., Sevastianova, K., Perttilä, J., Laurila, P., Sigrüener, A., et al. (2016) · Physiological Reports · doi:10.14814/phy2.12661 · Cited by 54
Cao, Y., Wang, C., Liu, J., Liu, Z., Ling, W., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep12951 · Cited by 53
Mulder, P., van den Hoek, A. M., & Kleemann, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169740 · Cited by 48
Nigro, D., Menotti, F., Cento, A. S., Serpe, L., Chiazza, F., Bello, F. D., Romaniello, F., Medana, C., Collino, M., Aragno, M., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.01.010 · Cited by 55
“Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease, affecting about 25% of the western world population [1], and represents the hepatic manifestation of the metabolic syndrome, also characterized by insulin resistance, dyslipidemia, hypertension, type 2 diabetes…”
Role of the intestinal microbiome in liver fibrosis development and new treatment strategies
Zhou, R., Fan, X., & Schnabl, B. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.005 · Cited by 59
Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease
Schultz, A., Mendonca, L. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2010) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.08.019 · Cited by 56
Yuen, K. C. J., Hjortebjerg, R., Ganeshalingam, A. A., Clemmons, D. R., & Frystyk, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1456195 · Cited by 59
Chronic stress induces steatohepatitis while decreases visceral fat mass in mice
Liu, Y.-Z., Chen, J.-K., Zhang, Y., Wang, X., Qu, S., & Jiang, C.-L. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-106 · Cited by 50
Park, E. Y., Lim, M. K., Oh, J., Cho, H., Bae, M. J., Yun, E. H., Kim, D., & Shin, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063439 · Cited by 51
Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field
Gallego‐Durán, R., & Romero-Gómez, M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i24.2497 · Cited by 52
Verhaegh, P. L. M., Bavalia, R., Winkens, B., Masclee, A., Jonkers, D. M. A. E., & Koek, G. H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.024 · Cited by 57
Sim, W.-C., Lee, W., Sim, H., Lee, K.-Y., Jung, S.-H., Choi, Y., Kim, H., Kang, K. W., Lee, J.-Y., Choi, Y. J., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154000 · Cited by 58
Potential role ofHelicobacter pyloriinfection in nonalcoholic fatty liver disease
Li, M., Shen, Z., & Li, Y.-M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.7024 · Cited by 55
Eilam, Y., Pintel, N., Khattib, H., Shagug, N., Taha, R., & Avni, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213667 · Cited by 53
Association between metabolic syndrome and the development of non-alcoholic fatty liver disease
Wang, Y., Li, Y. Y., Nie, Y. Q., Zhou, Y. J., Cao, C. Y., & Xu, L. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1090 · Cited by 51
“The prevalence of NAFLD is 20-30% in Western populations (4,5) and 11-15% in Chinese populations (6,7).”
BackgroundDoycheva, I., & Loomba, R. S. (2014) · Advances in Therapy · doi:10.1007/s12325-013-0084-6 · Cited by 53
“the most common cause of chronic liver disease in children and adolescents, with a prevalence of 3–10%, and even up to 70% in obese children [1, 3].”
BackgroundChen, C., Zhang, C., Wang, X., Zhang, F., Zhang, Z., Ma, P., & Feng, S. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001601 · Cited by 50
Ashworth, W. B., Davies, N. A., & Bogle, I. D. L. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005105 · Cited by 54
“As of 2014, 3.2 million people in the UK, 32 million people in Europe and 29.1 million people in the USA were estimated to suffer from diabetes.”
BackgroundInfluentialRoutine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base
Mahawar, K. K., Parmar, C. D., Graham, Y. N. H., Abouleid, A., Carr, W. R. J., Jennings, N., Schroeder, N., & Small, P. K. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1916-z · Cited by 50
Younossi, Z. M., Zheng, L., Stepanova, M., Henry, L., Venkatesan, C., & Mishra, A. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000071 · Cited by 49
Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future
Rahimlou, M., Ahmadnia, H., & Hekmatdoost, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i25.2597 · Cited by 49
Li, L., Martin-Levilain, J., Jiménez‐Sánchez, C., Karaca, M., Foti, M., Martinou, J., & Maechler, P. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007601 · Cited by 52
“Hepatic lipid accumulation characterizes nonalcoholic fatty liver disease (NAFLD)(3) that has become the most common chronic liver disease (2, 3).”
BackgroundKim, S.-A., & Shin, S. (2020) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2020-214568 · Cited by 51
Tran, C. D., Grice, D. M., Wade, B., Kerr, C. A., Bauer, D. C., Li, D., & Hannan, G. N. (2015) · Future Microbiology · doi:10.2217/fmb.15.54 · Cited by 48
Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease
Norris, G. H., & Blesso, C. N. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux004 · Cited by 50
Bellatorre, A., Scherzinger, A. L., Stamm, E. R., Martinez, M., Ringham, B. M., & Dabelea, D. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.09.008 · Cited by 51
“Despite interest and research in metabolic risks associated with these intrauterine exposures, there are limited data on potential associations with either adolescent liver fat accumulation or nonalcoholic fatty liver disease (NAFLD), an increasingly prevalent condition in the pediatric population.(6) Elevated viscera…”
Kirovski, G., Gäbele, E., Dorn, C., Moleda, L., Niessen, C., Weiß, T. S., Wobser, H., Schacherer, D., Buechler, C., Wasmuth, H. E., et al. (2010) · PubMed · doi:10.5283/epub.37048 · Cited by 45
Krupp, D., Johner, S. A., Kalhoff, H., Buyken, A. E., & Remer, T. (2012) · Journal of Nutrition · doi:10.3945/jn.111.150540 · Cited by 48
Kavanagh, K., Espeland, M. A., Sutton‐Tyrrell, K., Barinas‐Mitchell, E., Khoudary, S. R. E., & Wildman, R. P. (2013) · Obesity · doi:10.1002/oby.20077 · Cited by 43
“Fatty liver has been considered the hepatic manifestation of MS (3); however it has been recently recognized that ectopic liver fat accumulation has independent associations with insulin resistance and the cardiovascular risk biomarkers included in the MS definition (4-6).”
BackgroundZhao, J., Zhao, Y., Wang, H., Gu, X., Ji, J., & Gao, C. (2011) · Nutrition Journal · doi:10.1186/1475-2891-10-49 · Cited by 50
Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model
Müller, P., Messmer, M., Bayer, M., Pfeilschifter, J. M., Hintermann, E., & Christen, U. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.02.007 · Cited by 48
Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review
Tovo, C. V., Fernandes, S. A., Buss, C., & de Mattos, A. A. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i6.326 · Cited by 42
Clinical Manifestations and Diagnosis of Non-Alcoholic Fatty Liver Disease
Khoonsari, M., Azar, M. R. M. H., Ghavam, R., Hatami, K., Asobar, M., Gholami, A., Rajabi, A., Tameshkel, F. S., Amirkalali, B., & Sohrabi, M. (2017) · Iranian journal of pathology · doi:10.30699/ijp.2017.25038 · Cited by 54
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis
Khoo, N. K. H., Fazzari, M., Chartoumpekis, D. V., Li, L., Guimarães, D. A., Arteel, G. E., Shiva, S., & Freeman, B. Α. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101132 · Cited by 48
“The most common risk factors associated with NAFLD are obesity, type 2 diabetes and dyslipidemia, with the prevalence of NAFLD occurring in 80–90% of obese adults [1,2].”
BackgroundScragg, J., Avery, L., Cassidy, S., Taylor, G., Haigh, L., Boyle, M., Trenell, M. I., Anstee, Q. M., McPherson, S., & Hallsworth, K. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000231 · Cited by 44
Mirhafez, S. R., Dehabeh, M., Hariri, M., Farimani, A. R., Movahedi, A., Naderan, R. D., Jamialahmadi, T., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73234-9_2 · Cited by 51
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.